We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (JEMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01185717
Recruitment Status : Completed
First Posted : August 20, 2010
Last Update Posted : June 2, 2014
Information provided by (Responsible Party):

August 19, 2010
August 20, 2010
June 2, 2014
September 2010
May 2012   (Final data collection date for primary outcome measure)
Prevalence of anti-JCV antibodies [ Time Frame: Single timepoint (Day 1) ]
Prevalence of anti-JCV antibodies will be estimated as the number of participants with anti-JCV antibodies detected in serum divided by the total number of participants with a serum sample that was evaluated.
Estimate the prevalence of anti-JCV antibodies in MS patients [ Time Frame: one year ]
Complete list of historical versions of study NCT01185717 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)
Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients
The objective of the study is to estimate the prevalence of anti-JCV antibodies in multiple sclerosis (MS) participants.
This is a cross-sectional, multi-center, multi-national, epidemiological study to estimate the prevalence of anti-JCV antibody in MS participants. This study will provide an estimate of the prevalence of anti-JCV antibody in the MS population and will investigate inter-country differences.
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Multiple Sclerosis (MS) patients will be enrolled in Europe, Canada, and Australia.

Patient enrollment from each country will be commensurate with the distribution of MS patients among all participating countries.

Multiple Sclerosis
Not Provided
Not Provided
da Silva AM, Santos ME; Portuguese JEMS Study Investigators. JCV epidemiology in MS (JEMS)--epidemiology of anti-JCV antibody prevalence in multiple sclerosis patients--Portuguese data. J Neurol Sci. 2014 Feb 15;337(1-2):119-22. doi: 10.1016/j.jns.2013.11.031. Epub 2013 Dec 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2012
May 2012   (Final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • All candidates for this study must have the ability to understand the purpose of the study and provide signed and dated informed consent.
  • All patients with a diagnosis of Multiple Sclerosis (MS) of any type, irrespective of their treatment, are eligible to participate once.

Key Exclusion Criteria:

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
Not Provided
Australia,   Austria,   Belgium,   Canada,   Czech Republic,   Germany,   Ireland,   Netherlands,   Portugal,   Switzerland,   United Kingdom
Not Provided
Not Provided
Not Provided
Study Director: Medical Director Biogen
May 2014